Investigator-Initiated Studies: Internal Pharma Review

We have all seen it happen. A brilliant investigator approaches us at a medical conference, eyes bright with a research idea that could reshape how we understand a disease trajectory or a drug's real-world behavior in patients who were never enrolled in our registrational trials. The concept is sound, the unmet need is real, and the science is compelling. But somewhere between that initial spark of curiosity and the moment a first patient is enrolled, a long and often invisible machinery begins to turn — one that determines whether a promising idea receives the support it deserves or quietly dissolves into the space between enthusiasm and institutional capacity.

The investigator-initiated trial is one of the most misunderstood structures in our industry. Because the investigator holds the regulatory sponsorship, many assume the pharmaceutical company's role is purely transactional: write a cheque, ship the drug, move on. The reality is far more nuanced. Our internal review processes exist not as gatekeeping exercises, but as governance frameworks that protect patients, safeguard scientific integrity, and ensure that every piece of research we support carries genuine potential to improve the care pathway for people living with the conditions we study. Understanding how these processes work — and why they take the time they do — is essential for anyone navigating the intersection of academic ambition and industry partnership.

Defining the Regulatory Boundaries of Investigator-Initiated Research

Before we can talk about how we evaluate a proposal, we need to be honest about what an investigator-initiated study actually is — and what it is not. In an IIT or IIS, the independent investigator or the academic institution they represent acts as the regulatory sponsor. This is not a technicality. It means this individual or institution assumes full responsibility for study initiation, protocol design, regulatory filings such as IND or CTA applications, operational execution, safety reporting, and data analysis. The weight of that obligation is enormous, and it shapes every conversation we have with investigators who seek our support.

What we as a pharmaceutical company can offer is deliberately bounded. We can provide financial grants, investigational drug products, active comparator or placebo supplies, diagnostic assays, or technical resources — but always under a written agreement that makes clear the company does not assume regulatory sponsorship. This distinction matters profoundly for patient safety and for the integrity of the data generated. Under frameworks like 21 CFR 312, the regulations define sponsor and investigator responsibilities with specificity that leaves little room for ambiguity, and our internal processes are designed to honour those boundaries rather than blur them.

The IIT exists at the intersection of independent scientific inquiry and structured industry support — and the review process must protect both the investigator's autonomy and the patient's trust.

The moment we lose sight of this regulatory architecture, problems follow. Investigators sometimes arrive expecting us to co-design their protocols or manage their regulatory submissions. Our medical science liaison teams work hard to set expectations early, clarifying that while MSLs are the natural first point of contact and can facilitate the submission process, they cannot solicit IIT proposals or influence protocol design. The concept must originate independently from the investigator's own scientific questions. This is not bureaucratic pedantry — it is a compliance safeguard that protects every stakeholder involved.

Strategic Alignment and Scientific Merit: The Initial Screening Phase

When a concept proposal arrives — typically through an online company portal or via our MSL network — it enters a preliminary screening phase that is, in many ways, the most consequential moment in the entire lifecycle. This is where we first ask whether the proposed research connects to our therapeutic focus areas, whether it addresses a genuine medical need, and whether the scientific hypothesis is robust enough to withstand scrutiny.

The initial concept submission is deliberately lightweight. We are not asking for a 50-page protocol at this stage. What we need is a clear articulation of the research question, the proposed study design at a high level, the patient population, and a preliminary sense of the investigator's capability and institutional resources. The concept-to-protocol submission window typically runs 60 to 90 days, giving investigators time to refine their ideas after initial feedback while maintaining forward momentum.

What we are looking for during this screening is not perfection but alignment. A proposal can be scientifically elegant and still fall outside our strategic therapeutic focus areas. Conversely, a modest study that addresses a critical gap in our understanding of how a therapy performs in an underrepresented population can command serious attention despite its smaller scale. The screening phase assesses several dimensions simultaneously:

• Scientific design quality — Is the hypothesis testable? Is the methodology sound? Will the data, regardless of outcome, contribute meaningfully to the evidence base?
• Strategic alignment — Does this research address a defined therapeutic focus area where our portfolio or pipeline has a genuine stake in the answers?
• Ethical standards — Does the proposal meet institutional review board requirements and align with Good Clinical Practice expectations?
• Investigator qualification — Does the principal investigator have the curriculum vitae, the site infrastructure, and the track record to execute what they are proposing?
• Medical need — Is there a genuine gap in clinical understanding that this study could help close?

This last criterion — medical need — is the one that carries the most weight in our deliberations, even when it is harder to quantify than the others. We have all seen studies that check every methodological box but answer questions no one in the clinical community is actually asking. The proposals that move us are the ones where you can feel the patient burden behind the research question, where the investigator is clearly motivated by a gap they have observed at the bedside.

Navigating the Internal IIT Committee Workflow and Governance

Once a concept passes initial screening, it enters our formal internal review — and this is where the governance structure becomes visible. Most pharmaceutical companies maintain dedicated IIT review committees that bring together representatives from medical affairs, clinical development, regulatory, legal, and sometimes commercial strategy. The composition of this committee is intentional: no single function should drive the decision, because the considerations are too multifaceted.

The workflow moves from concept approval through to full protocol and detailed budget review. After preliminary screening, the company requests a comprehensive protocol and a line-item budget from the investigator. This is a critical handoff point. The quality of the full protocol submission often reveals whether the initial concept was a genuinely developed research idea or a half-formed ambition that needed considerably more work. Investigators who invest in a rigorous full protocol at this stage signal both their commitment and their capability.

The table below captures the typical governance workflow and its key decision points:

The committee evaluates proposals against the criteria we have already discussed, but the full protocol stage adds layers of specificity. Budget review is particularly important: we are assessing not just whether the numbers add up, but whether they reflect fair market value for the work proposed. This is a compliance imperative. If a pharmaceutical company funds research at rates that exceed fair market value, it risks creating the appearance of inducement — a violation that regulatory bodies take seriously and that undermines the credibility of the entire IIT ecosystem.

Ensuring Compliance: Fair Market Value and Regulatory Independence

Compliance in the IIT space is not a box-ticking exercise — it is the structural foundation on which our support rests. Every written agreement, every budget line item, every interaction between our teams and the investigator must reinforce a simple truth: the investigator is the sponsor, and our role is that of a supportive partner whose contributions are bounded by regulatory and ethical frameworks.

Fair market value assessment deserves particular attention because it is the area where well-intentioned partnerships most frequently encounter friction. When an investigator submits a budget, we evaluate it against comparable studies, institutional cost structures, and published benchmarks for clinical research operations in the relevant geography and therapeutic area. If the proposed costs exceed what we assess as fair market value, we do not simply reject the budget — we enter a dialogue with the investigator to understand the reasoning and find an appropriate middle ground.

This process protects everyone involved:

• The investigator gains confidence that their funding will withstand external audit and regulatory scrutiny
• Our company demonstrates that support is provided on a principled, arms-length basis
• The patients enrolled in the resulting study can trust that the research was not influenced by financial incentives that might compromise scientific objectivity
• The broader research community benefits from a model that prioritises transparency and reproducibility

Legal compliance extends beyond budgets. Written agreements must clearly delineate intellectual property rights, publication rights, data ownership, and safety reporting obligations. Investigators retain the right to publish their findings — this is non-negotiable — but the agreement typically includes provisions for mutual review of manuscripts to ensure accuracy and to protect confidential company information. These provisions exist not to suppress inconvenient data, but to ensure that published findings meet the standards of scientific rigour that the research community and, ultimately, patients deserve.

When we fund an IIT, we are not buying a result — we are investing in a question, and the answer belongs to science.

The regulatory independence of the investigator must remain intact throughout the study lifecycle. This means that while we may provide our drug product and financial support, we do not direct how the study is conducted, we do not control the data, and we do not interfere with safety reporting obligations that the investigator owes to their institutional review board and relevant regulatory authorities. Our compliance teams work continuously to maintain this separation, and it is one of the reasons the internal review process exists in the first place — to ensure that every partnership is structured in a way that preserves the investigator's autonomy as the regulatory sponsor.

Optimising the 6-to-12 Month Approval Cycle

The overall IIT development and approval cycle typically runs 6 to 12 months from initial concept submission to final approval and contracting. For investigators accustomed to the pace of academic grant funding, this can feel interminable. For those of us who have lived inside these processes, we know that every month of that timeline serves a purpose — but we also recognise that the experience for the investigator is not always transparent, and that opacity erodes trust.

Reducing cycle time without compromising governance rigour is one of the most meaningful operational improvements our industry can pursue. Several approaches have shown real impact:

1. Early-stage investigator education — When MSL teams and medical affairs professionals provide clear guidance on submission requirements, strategic focus areas, and common protocol deficiencies before a concept is submitted, the quality of initial proposals rises and the need for revision cycles decreases.

2. Standardised protocol templates and budget frameworks — Providing investigators with structured templates that reflect our review criteria helps them anticipate what the committee needs to see and reduces the back-and-forth that inflates timelines unnecessarily.

3. Tiered review pathways — Not every IIT proposal carries the same complexity or risk. A small, single-site pharmacokinetic study does not require the same depth of review as a multi-centre randomised trial. Tiered pathways allow simpler proposals to move through the system faster while reserving the full committee deliberation for studies that genuinely warrant it.

4. Dedicated IIT programme management — Organisations that invest in a centralised programme office with clear ownership of the end-to-end process consistently achieve faster cycle times and higher investigator satisfaction. The alternative — fragmented ownership across multiple functions with no single point of accountability — is the single greatest source of delay.

5. Digital submission platforms with real-time status tracking — Investigators deserve to know where their proposal stands. Platforms that provide visibility into the review stage, anticipated decision dates, and outstanding requirements reduce the anxiety that comes with silence and demonstrate respect for the investigator's time and effort.

Each of these interventions addresses a specific friction point in the process, but their combined effect is something more significant than operational efficiency. They signal to the investigator community that we take their research ambitions seriously, that we understand the patient burden motivating their work, and that our governance processes exist to enable meaningful research — not to obstruct it.

The Human Reality Behind Every Approval

There is a moment in every IIT review meeting — usually late in the discussion, after the budget has been dissected and the protocol design has been debated — when someone around the table pauses and asks a version of the same question: Who does this study help? Not in the abstract sense of advancing therapeutic knowledge, but in the specific, lived-experience sense of whether the findings will change something for a patient sitting in a clinic next month or next year.

That question is the conscience of our internal review process. The scientific design matters, the compliance architecture matters, the budget and the contracting and the regulatory framework all matter — but they are the scaffolding, not the purpose. The purpose is the patient whose care pathway could be improved by data that does not yet exist, whose treatment decisions are currently made on incomplete evidence, whose experience of living with their condition is shaped by the gaps in our collective understanding.

When we get the IIT review process right — when we balance rigour with responsiveness, compliance with compassion, governance with genuine scientific curiosity — we create space for investigators to pursue the questions that matter most. And when we get it wrong, when process becomes an end in itself rather than a means to better research, the cost is measured not in delayed timelines but in delayed answers to questions that patients cannot afford to wait for.

Our industry's commitment to investigator-initiated research is, at its heart, an admission that we do not have all the answers. The registrational trials that bring therapies to market are designed to answer specific regulatory questions, and they do so with rigour. But they cannot answer every question a clinician faces at the bedside, every nuance of how a therapy behaves in the full spectrum of real-world patients, every gap in our understanding of disease that only becomes visible when someone asks the right question in the right population. Investigator-initiated studies fill that space, and our internal review processes must be designed to honour that role — protecting scientific integrity, regulatory compliance, and patient trust while never losing sight of the human reality that makes the entire enterprise worthwhile.